Enzymatica Q3: Initial take – Sales not in line with our expectations - Redeye

Redeye provides an initial take on Enzymatica’s Q3 2023 report. Sales during the quarter amounted to SEK13.3m (SEK18.5m) compared to our sales estimate of SEK18.3m. Moreover, EBIT came in at SEK-8.7m (SEK-12.6m), and the cash position at the end of the period amounted to SEK13.0m. Overall, the sales were lower than expected; however, EBIT was better than anticipated. We will provide a more in-depth update shortly and expect to make some downward sales estimate changes based on today’s report.

Länk till analysen i sin helhet: https://www.redeye.se/research/955964/enzymatica-q3-initial-take-sales-not-in-line-with-our-expectations?utm_source=finwire&utm_medium=RSS